New insider activity at Alector ( (ALEC) ) has taken place on March 6, 2025.
In a recent series of transactions involving Alector stock, several top executives have made significant sales. CFO and CBO Marc Grasso sold 18,091 shares for a total of $26,412. President and Head of R&D Sara Kenkare-Mitra parted with 29,073 shares, amounting to $42,446. CMO Gary Romano sold 16,306 shares, bringing in $23,806. Meanwhile, CEO Arnon Rosenthal made the largest sale, offloading 40,330 shares for $58,881.
Recent Updates on ALEC stock
Alector’s recent earnings call and financial reports highlighted both achievements and challenges. The company reported a significant increase in collaboration revenue for Q4 2024, driven by successful partnerships, although year-over-year growth remained flat. The FDA granted breakthrough therapy designation for Latozinemab, enhancing its market potential. Alector maintains a strong cash position, expected to fund operations through 2026, supporting its strategic objectives and research initiatives. However, high R&D expenses and uncertainties in clinical trial timelines pose challenges. The company remains optimistic about advancing its clinical programs, with key milestones anticipated in the coming years, including pivotal trial data and enrollment completions. These developments are shaping analysts’ perspectives on Alector’s future performance.
More about Alector
YTD Price Performance: -23.02%
Average Trading Volume: 999,105
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $144.2M